Dynavax Technologies Corp.

+0.47 (+6.41%)
Business Deals, Other Pre-Announcement

Valneva Announces Agreement With UK Governement

Published: 09/14/2020 05:18 GMT
Dynavax Technologies Corp. (DVAX) - Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted Covid-19 Vaccine.
Inactivated, Adjuvanted Sars-cov-2 Vaccine Candidate Scheduled to Enter First Clinical Studies in December 2020.
Expects Vla2001 to Enter Clinical Studies by End of 2020 and to Potentially Reach Regulatory Approval in the Second Half of 2021.
Dynavax Will Provide Cpg 1018 to Produce Up to 190 Million Doses Over a Five Year Period to Support Valneva’s Contract With Uk Gov.
Separately Announced Today an Agreement With the Uk Government to Provide Up to 190 Million Doses of Vla2001.
Dynavax Will Supply Cpg 1018 to Produce Up to 100 Million Doses of Vaccine in 2021.
Valneva Has the Option to Purchase Up to an Additional 90 Million Doses Through 2025.